Who is sponsoring NCT06251583?

NCT06251583 is sponsored by Miguel A ngel Garci-a Urena.

What drugs are being tested in NCT06251583?

Interventions in NCT06251583: duramesh suture.

What condition does NCT06251583 study?

NCT06251583 studies Incisional Hernia of Anterior Abdominal Wall, Dehiscence Wound, Wound Infection.

Is NCT06251583 still recruiting?

NCT06251583 is currently status unknown. Last updated 9 February 2024.

Last reviewed 2024-02-09 · How we verify

NCT06251583: INDURATE

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Prevention of Incisional Hernia With Mesh-suture at Umbilical Trocar Site.

Status unknown Phase 3 Last updated 9 February 2024

What this trial tests

Phase 3 trial testing duramesh suture in Incisional Hernia of Anterior Abdominal Wall in 124 participants. Status unknown.

Timeline

22 March 2023

Primary endpoint
22 March 2024

30 June 2025

Quick facts

Lead sponsor	Miguel A ngel Garci-a Urena
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	prevention
Enrollment	124
Start date	22 March 2023
Primary completion	22 March 2024
Estimated completion	30 June 2025
Sites	1 location across Spain

Drugs / interventions tested

duramesh suture

Conditions studied

Incisional Hernia of Anterior Abdominal Wall — all drugs for Incisional Hernia of Anterior Abdominal Wall →
Dehiscence Wound — all drugs for Dehiscence Wound →
Wound Infection — all drugs for Wound Infection →

Sponsor

Miguel A ngel Garci-a Urena

Who can join

18 and older, any sex, with Incisional Hernia of Anterior Abdominal Wall or Dehiscence Wound. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Incisional hernia related to the umbilical trocar site is probably the most frequent complication after laparoscopic surgical procedures. However, this is an underestimated sequelae of laparoscopic surgery which may involve an important morbidity and an increase in healthcare costs. The incidence of incisional trocar site hernia ranges from 20 to 35% of patients after laparoscopic surgery depending on the different investigations. Prophylactic meshes have been tried in an attempt to reduce the incidence of this complication in obese patients. In that sense, suture-meshes can be an alternative to conventional meshes to improve the incidence of incisional hernias. INDURATE TRIAL aims to test if suture-mesh is capable of reducing the incidence of incisional hernia in patients with risk factors for the development of this frequent complication when compared with conventional monofilament sutures.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06251583 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Miguel A ngel Garci-a Urena
Last refreshed: 9 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06251583.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing